2013
Effect of Escitalopram on Mental Stress–Induced Myocardial Ischemia: Results of the REMIT Trial
Jiang W, Velazquez EJ, Kuchibhatla M, Samad Z, Boyle SH, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, O’Connor C. Effect of Escitalopram on Mental Stress–Induced Myocardial Ischemia: Results of the REMIT Trial. JAMA 2013, 309: 2139-2149. PMID: 23695483, PMCID: PMC4378823, DOI: 10.1001/jama.2013.5566.Peer-Reviewed Original ResearchConceptsMental stress-induced myocardial ischemiaStable coronary heart diseaseExercise-induced ischemiaCoronary heart diseaseMyocardial ischemiaHeart diseaseVentricular ejection fraction reductionStress-induced myocardial ischemiaMental stressRegional wall motion abnormalitiesEjection fraction reductionPlacebo-controlled trialST-segment depressionEffect of escitalopramTertiary medical centerWall motion abnormalitiesWeeks of escitalopramSignificant differencesEnd-point assessmentStressor taskEscitalopram groupCardiac eventsEscitalopram treatmentMore patientsTreat analysis
2003
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context
Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau J, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM, Investigators F. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European Journal Of Heart Failure 2003, 5: 537-544. PMID: 12921816, DOI: 10.1016/s1388-9842(03)00112-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin Receptor AntagonistsCaptoprilDouble-Blind MethodFemaleGlyceraldehyde-3-Phosphate DehydrogenasesHeart FailureHumansMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionPeptide FragmentsRandomized Controlled Trials as TopicTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsAcute Myocardial Infarction trialAngiotensin receptor blockadeMyocardial Infarction trialHeart failureMyocardial infarctionACEI trialsRenin-angiotensin system blockadePlacebo-controlled trialVentricular systolic dysfunctionActive-controlled trialEvidence-based careHigh-risk populationEvidence-based therapiesCardiovascular outcomesSystem blockadeSystolic dysfunctionBaseline characteristicsStandard treatmentRepresentative cohortPatientsMI trialsTrialsValsartanACEIsLVSD